Literature DB >> 32540221

A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.

Timothy I Miller1, Nicholas A Zoumberos2, Bryan Johnson3, Daniel R Rhodes4, Scott A Tomlins5, May P Chan6, Aleodor A Andea7, David R Lucas8, Jonathan B McHugh9, Noah Smith10, Kelly L Harms11, Chad Brewer12, Jasmine Saleh13, Rajiv M Patel14, Paul W Harms15.   

Abstract

Sarcomas on photodamaged skin vary in prognosis and management, but can display overlapping microscopic and immunophenotypic features. Improved understanding of molecular alterations in these tumors may provide diagnostic and therapeutic insights. We characterized 111 cutaneous sarcomatoid malignancies and their counterparts, including primary cutaneous angiosarcoma (n = 7), atypical fibroxanthoma (AFX) (n = 21), pleomorphic dermal sarcoma (PDS) (n = 17), extracutaneous undifferentiated pleomorphic sarcoma (n = 8), cutaneous leiomyosarcoma (LMS) (n = 5), extracutaneous LMS (n = 9), sarcomatoid squamous cell carcinoma (spindle cell squamous cell carcinoma) (S-SCC) (n = 24), and conventional cutaneous squamous cell carcinoma (SCC) (n = 20), by next-generation sequencing (NGS) using the StrataNGS panel for copy number variations, mutations, and/or fusions in more than 60 cancer-related genes. TP53 mutations were highly recurrent in most groups. Angiosarcoma displayed previously reported MYC amplifications, as well as CCND1 gains. RB1 mutations were relatively restricted to cutaneous LMS. As previously reported, PIK3CA mutations occurred in AFX, whereas RAS activation was more frequent in PDS. CDKN2A mutations were recurrent in AFX and S-SCC, whereas PDS displayed frequent CDKN2A deletion. S-SCC displayed mutational similarity to conventional SCC. BRCA1/2 mutations were specific to tumors with disease progression. In a subset, we detected potential driver events novel to these tumor types: activating mutations in IDH2 (PDS), MAP2K1 (angiosarcoma, PDS), and JAK1 (S-SCC) and copy gains in FGFR1 (angiosarcoma, S-SCC), KIT (AFX), MET (PDS), and PDGFRA (PDS). Our findings confirm and expand the spectrum of known genomic aberrations, including potential targetable drivers, in cutaneous sarcomatoid malignancies. In addition, certain events are relatively specific to particular tumors within this differential diagnosis and hence might be diagnostically informative.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiosarcoma; Atypical fibroxanthoma; Leiomyosarcoma; Pleomorphic dermal sarcoma; Sarcomatoid carcinoma; Undifferentiated pleomorphic sarcoma

Year:  2020        PMID: 32540221     DOI: 10.1016/j.humpath.2020.06.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas.

Authors:  Paul Weisman; Kay J Park; Jin Xu
Journal:  Int J Gynecol Pathol       Date:  2022-03-01       Impact factor: 2.762

2.  Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers.

Authors:  Kelly L Harms; Lili Zhao; Bryan Johnson; Xiaoming Wang; Shannon Carskadon; Nallasivam Palanisamy; Daniel R Rhodes; Rahul Mannan; Josh N Vo; Jae Eun Choi; May P Chan; Douglas R Fullen; Rajiv M Patel; Javed Siddiqui; Vincent T Ma; Steven Hrycaj; Scott A McLean; Tasha M Hughes; Christopher K Bichakjian; Scott A Tomlins; Paul W Harms
Journal:  Clin Cancer Res       Date:  2021-02-05       Impact factor: 12.531

3.  Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.

Authors:  Scott A Tomlins; Daniel H Hovelson; Jennifer M Suga; Daniel M Anderson; Han A Koh; Elizabeth C Dees; Brendan McNulty; Mark E Burkard; Michael Guarino; Jamil Khatri; Malek M Safa; Marc R Matrana; Eddy S Yang; Alex R Menter; Benjamin M Parsons; Jennifer N Slim; Michael A Thompson; Leon Hwang; William J Edenfield; Suresh Nair; Adedayo Onitilo; Robert Siegel; Alan Miller; Timothy Wassenaar; William J Irvin; William Schulz; Arvinda Padmanabhan; Vallathucherry Harish; Anneliese Gonzalez; Abdul Hai Mansoor; Andrew Kellum; Paul Harms; Stephanie Drewery; Jayson Falkner; Andrew Fischer; Jennifer Hipp; Kat Kwiatkowski; Lorena Lazo de la Vega; Khalis Mitchell; Travis Reeder; Javed Siddiqui; Hana Vakil; D Bryan Johnson; Daniel R Rhodes
Journal:  JCO Precis Oncol       Date:  2021-08-19

4.  Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from squamous dysplastic precursors.

Authors:  Paul W Harms; Monique E Verhaegen; Kevin Hu; Steven M Hrycaj; May P Chan; Chia-Jen Liu; Marina Grachtchouk; Rajiv M Patel; Aaron M Udager; Andrzej A Dlugosz
Journal:  Mod Pathol       Date:  2021-09-30       Impact factor: 7.842

5.  The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma.

Authors:  Ingrid Ferreira; Alastair Droop; Olivia Edwards; Kim Wong; Victoria Harle; Omar Habeeb; Deepa Gharpuray-Pandit; Joseph Houghton; Katharina Wiedemeyer; Thomas Mentzel; Steven D Billings; Jennifer S Ko; Laszlo Füzesi; Kathleen Mulholland; Ivana Kuzmic Prusac; Bernadette Liegl-Atzwanger; Nicolas de Saint Aubain; Helen Caldwell; Laura Riva; Louise van der Weyden; Mark J Arends; Thomas Brenn; David J Adams
Journal:  Mod Pathol       Date:  2021-06-21       Impact factor: 7.842

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.